204 related articles for article (PubMed ID: 22207316)
1. Ex vivo enrichment of circulating anti-tumor T cells from both cutaneous and ocular melanoma patients: clinical implications for adoptive cell transfer therapy.
Mazzarella T; Cambiaghi V; Rizzo N; Pilla L; Parolini D; Orsenigo E; Colucci A; Modorati G; Doglioni C; Parmiani G; Maccalli C
Cancer Immunol Immunother; 2012 Aug; 61(8):1169-82. PubMed ID: 22207316
[TBL] [Abstract][Full Text] [Related]
2. Co-stimulation through 4-1BB/CD137 improves the expansion and function of CD8(+) melanoma tumor-infiltrating lymphocytes for adoptive T-cell therapy.
Chacon JA; Wu RC; Sukhumalchandra P; Molldrem JJ; Sarnaik A; Pilon-Thomas S; Weber J; Hwu P; Radvanyi L
PLoS One; 2013; 8(4):e60031. PubMed ID: 23560068
[TBL] [Abstract][Full Text] [Related]
3. Expansion and characterization of human melanoma tumor-infiltrating lymphocytes (TILs).
Nguyen LT; Yen PH; Nie J; Liadis N; Ghazarian D; Al-Habeeb A; Easson A; Leong W; Lipa J; McCready D; Reedijk M; Hogg D; Joshua AM; Quirt I; Messner H; Shaw P; Crump M; Sharon E; Ohashi PS
PLoS One; 2010 Nov; 5(11):e13940. PubMed ID: 21085676
[TBL] [Abstract][Full Text] [Related]
4. MART-1-specific melanoma tumor-infiltrating lymphocytes maintaining CD28 expression have improved survival and expansion capability following antigenic restimulation in vitro.
Li Y; Liu S; Hernandez J; Vence L; Hwu P; Radvanyi L
J Immunol; 2010 Jan; 184(1):452-65. PubMed ID: 19949105
[TBL] [Abstract][Full Text] [Related]
5. Characterization and comparison of 'standard' and 'young' tumour-infiltrating lymphocytes for adoptive cell therapy at a Danish translational research institution.
Donia M; Junker N; Ellebaek E; Andersen MH; Straten PT; Svane IM
Scand J Immunol; 2012 Feb; 75(2):157-67. PubMed ID: 21955245
[TBL] [Abstract][Full Text] [Related]
6. Phenotype and function of T cells infiltrating visceral metastases from gastrointestinal cancers and melanoma: implications for adoptive cell transfer therapy.
Turcotte S; Gros A; Hogan K; Tran E; Hinrichs CS; Wunderlich JR; Dudley ME; Rosenberg SA
J Immunol; 2013 Sep; 191(5):2217-25. PubMed ID: 23904171
[TBL] [Abstract][Full Text] [Related]
7. Phase II clinical trial of adoptive cell therapy for patients with metastatic melanoma with autologous tumor-infiltrating lymphocytes and low-dose interleukin-2.
Nguyen LT; Saibil SD; Sotov V; Le MX; Khoja L; Ghazarian D; Bonilla L; Majeed H; Hogg D; Joshua AM; Crump M; Franke N; Spreafico A; Hansen A; Al-Habeeb A; Leong W; Easson A; Reedijk M; Goldstein DP; McCready D; Yasufuku K; Waddell T; Cypel M; Pierre A; Zhang B; Boross-Harmer S; Cipollone J; Nelles M; Scheid E; Fyrsta M; Lo CS; Nie J; Yam JY; Yen PH; Gray D; Motta V; Elford AR; DeLuca S; Wang L; Effendi S; Ellenchery R; Hirano N; Ohashi PS; Butler MO
Cancer Immunol Immunother; 2019 May; 68(5):773-785. PubMed ID: 30747243
[TBL] [Abstract][Full Text] [Related]
8. Costimulation through the CD137/4-1BB pathway protects human melanoma tumor-infiltrating lymphocytes from activation-induced cell death and enhances antitumor effector function.
Hernandez-Chacon JA; Li Y; Wu RC; Bernatchez C; Wang Y; Weber JS; Hwu P; Radvanyi LG
J Immunother; 2011 Apr; 34(3):236-50. PubMed ID: 21389874
[TBL] [Abstract][Full Text] [Related]
9. Activation and propagation of tumor-infiltrating lymphocytes on clinical-grade designer artificial antigen-presenting cells for adoptive immunotherapy of melanoma.
Forget MA; Malu S; Liu H; Toth C; Maiti S; Kale C; Haymaker C; Bernatchez C; Huls H; Wang E; Marincola FM; Hwu P; Cooper LJ; Radvanyi LG
J Immunother; 2014; 37(9):448-60. PubMed ID: 25304728
[TBL] [Abstract][Full Text] [Related]
10. Melanocortin 1 Receptor-derived peptides are efficiently recognized by cytotoxic T lymphocytes from melanoma patients.
González FE; Ramírez M; Allerbring EB; Fasching N; Lundqvist A; Poschke I; Achour A; Salazar-Onfray F
Immunobiology; 2014 Mar; 219(3):189-97. PubMed ID: 24192537
[TBL] [Abstract][Full Text] [Related]
11. TGF-beta1 induces preferential rapid expansion and persistence of tumor antigen-specific CD8+ T cells for adoptive immunotherapy.
Liu S; Etto T; Rodríguez-Cruz T; Li Y; Wu C; Fulbright OJ; Hwu P; Radvanyi L; Lizée G
J Immunother; 2010 May; 33(4):371-81. PubMed ID: 20386469
[TBL] [Abstract][Full Text] [Related]
12. Generation of tumor-infiltrating lymphocyte cultures for use in adoptive transfer therapy for melanoma patients.
Dudley ME; Wunderlich JR; Shelton TE; Even J; Rosenberg SA
J Immunother; 2003; 26(4):332-42. PubMed ID: 12843795
[TBL] [Abstract][Full Text] [Related]
13. Lymphocytes cytotoxic to uveal and skin melanoma cells from peripheral blood of ocular melanoma patients.
Kan-Mitchell J; Liggett PE; Harel W; Steinman L; Nitta T; Oksenberg JR; Posner MR; Mitchell MS
Cancer Immunol Immunother; 1991; 33(5):333-40. PubMed ID: 1831067
[TBL] [Abstract][Full Text] [Related]
14. Randomized selection design trial evaluating CD8+-enriched versus unselected tumor-infiltrating lymphocytes for adoptive cell therapy for patients with melanoma.
Dudley ME; Gross CA; Somerville RP; Hong Y; Schaub NP; Rosati SF; White DE; Nathan D; Restifo NP; Steinberg SM; Wunderlich JR; Kammula US; Sherry RM; Yang JC; Phan GQ; Hughes MS; Laurencot CM; Rosenberg SA
J Clin Oncol; 2013 Jun; 31(17):2152-9. PubMed ID: 23650429
[TBL] [Abstract][Full Text] [Related]
15. Achievements and challenges of adoptive T cell therapy with tumor-infiltrating or blood-derived lymphocytes for metastatic melanoma: what is needed to achieve standard of care?
Svane IM; Verdegaal EM
Cancer Immunol Immunother; 2014 Oct; 63(10):1081-91. PubMed ID: 25099366
[TBL] [Abstract][Full Text] [Related]
16. Large-scale bioreactor expansion of tumor-infiltrating lymphocytes.
Sadeghi A; Pauler L; Annerén C; Friberg A; Brandhorst D; Korsgren O; Tötterman TH
J Immunol Methods; 2011 Feb; 364(1-2):94-100. PubMed ID: 21111743
[TBL] [Abstract][Full Text] [Related]
17. Persistence of multiple tumor-specific T-cell clones is associated with complete tumor regression in a melanoma patient receiving adoptive cell transfer therapy.
Zhou J; Dudley ME; Rosenberg SA; Robbins PF
J Immunother; 2005; 28(1):53-62. PubMed ID: 15614045
[TBL] [Abstract][Full Text] [Related]
18. Generation of autologous tumor-specific T cells for adoptive transfer based on vaccination, in vitro restimulation and CD3/CD28 dynabead-induced T cell expansion.
Brimnes MK; Gang AO; Donia M; Thor Straten P; Svane IM; Hadrup SR
Cancer Immunol Immunother; 2012 Aug; 61(8):1221-31. PubMed ID: 22237888
[TBL] [Abstract][Full Text] [Related]
19. CXCR1 as a novel target for directing reactive T cells toward melanoma: implications for adoptive cell transfer immunotherapy.
Sapoznik S; Ortenberg R; Galore-Haskel G; Kozlovski S; Levy D; Avivi C; Barshack I; Cohen CJ; Besser MJ; Schachter J; Markel G
Cancer Immunol Immunother; 2012 Oct; 61(10):1833-47. PubMed ID: 22441657
[TBL] [Abstract][Full Text] [Related]
20. Tumor-specific CD4+ melanoma tumor-infiltrating lymphocytes.
Friedman KM; Prieto PA; Devillier LE; Gross CA; Yang JC; Wunderlich JR; Rosenberg SA; Dudley ME
J Immunother; 2012 Jun; 35(5):400-8. PubMed ID: 22576345
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]